Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsTOPICALStandard

LICART

DICLOFENAC EPOLAMINE

Standard Dose
1.3%
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview LICART is listed in Drugs@FDA under application 206976 (NDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient DICLOFENAC EPOLAMINE Form and strength SYSTEM;TOPICAL - 1.3% Sponsor IBSA INST BIO Submission history Latest submission status date: 2026-03-27 00:00:00.

Structured Monograph

Clinical summary

Approval overview LICART is listed in Drugs@FDA under application 206976 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient DICLOFENAC EPOLAMINE Form and strength SYSTEM;TOPICAL - 1.3% Sponsor IBSA INST BIO Submission history Latest submission status date: 2026-03-27 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.